Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma
Conditions: Clinical Stage IIA Cutaneous Melanoma AJCC v8 Interventions: Drug: Atorvastatin; Drug: Placebo Administration; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Other: Electronic Health Record Review Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University; Kuni Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 5, 2023 Category: Research Source Type: clinical trials
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 5, 2023 Category: Pharmaceuticals Source Type: clinical trials
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Conditions: Melanoma Sponsors: University Hospital, Grenoble; Etablissement Fran çais du Sang Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2023 Category: Research Source Type: clinical trials
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda ® in Participants With Stage II and III Melanoma
Conditions: Melanoma Interventions: Drug: GME751; Drug: Keytruda - EU; Drug: Keytruda - US Sponsors: Sandoz Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: Sintilimab; Drug: Chemotherapy Sponsors: Fudan University; Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Unresectable Melanoma Interventions: Procedure: Biospecimen Collection; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Biological: Interleukin-2; Biological: Lifileucel; Procedure: Magnetic Resonance Imaging; Procedure: Multigated Acquisition Scan; Procedure: Tumor Resection Sponsors: University of Kansas Medical Center; National Cancer Institute (NCI); Iovance Biotherapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Conditions: Stage III Malignant Melanoma of Skin AJCC V6; Stage IV Malignant Melanoma of Skin Interventions: Biological: TAPCells vaccine Sponsors: University of Chile Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma Interventions: Drug: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination Sponsors: Melanoma Institute Australia; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Conditions: Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma Interventions: Drug: CTX-8371 Sponsors: Compass Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma; BCC Interventions: Drug: 5-Fluorouracil; Other: SURGERY Sponsors: University of Aleppo; Aleppo University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Conditions: Advanced Solid Tumor; Metastatic Colorectal Carcinoma; Head and Neck Squamous Cell Carcinoma; Non-small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma Interventions: Drug: FPI-2053; Drug: [111In]-FPI-2107; Drug: [225Ac]-FPI-2068 Sponsors: Fusion Pharmaceuticals Inc.; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Conditions: Melanoma; Non-small Cell Lung Cancer Interventions: Other: Evaluation of ctDNA using the F1T after 1 year of immunotherapy Sponsors: Massachusetts General Hospital; Foundation Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 27, 2023 Category: Research Source Type: clinical trials
Shadow for All, a Citizenship Science Study to Promote the Prevention of Skin Cancer
Conditions: Skin Cancer Interventions: Behavioral: Adhesion to the use of collective shadow; Behavioral: Adhesion to the use of sun protector; Behavioral: Adhesion to the use of the information disposed in the infographic; Behavioral: Adhesion to the health literacy sessions in the interventional groups Sponsors: Universidade do Porto Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Synchronous or Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma With Oligometastases.
Conditions: Advanced Esophageal Squamous Carcinoma With Oligometastases Interventions: Radiation: simultaneous with radiotherapy; Radiation: synchronous with radiotherapy Sponsors: West China Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 22, 2023 Category: Research Source Type: clinical trials
Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma; Radiotherapy; Radiosensitizer; Pirfenidone Interventions: Drug: Pirfenidone; Drug: Placebo Sponsors: Nanfang Hospital, Southern Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
